Genoa Ventures

Alida Biosciences is a biotechnology company established in 2020 and based in San Diego, California. The company specializes in developing innovative RNA analysis tools aimed at enhancing human health. By focusing on advancements in RNA biology, Alida Biosciences creates technologies that facilitate the discovery of new drugs and therapeutics. Its work is designed to support the development of medical treatments and diagnostic assays, ultimately enabling patients to access effective healthcare solutions.

Aqtual is a biotechnology company developing a novel analytical platform for cancer drug treatment. Its platform captures molecular signals from circulating deoxyribonucleic acid (DNA) to enhance diagnostic accuracy and enable personalized cancer treatment.

BRAINBox Solutions develops and manufactures diagnostic tests for traumatic brain injury, focusing on mild TBI. The company offers a multi-modality platform that combines blood biomarker panels with neurocognitive testing and point-of-care instruments to provide objective assessments of injury and recovery potential. Its quantitative test integrates injury-related blood biomarkers with computerized neurological assessments and delivers an AI-driven score to aid clinicians in predicting recovery and identifying ongoing symptoms. Founded in 2002 and based in Richmond, Virginia, BRAINBox Solutions serves healthcare providers with tools designed to improve diagnostic accuracy and prognosis for patients with mild TBI.

BrightSpec specializes in innovative analytical chemistry services, utilizing its proprietary Fourier transform molecular rotational resonance (FT-MRR) technology. Based in Charlottesville, Virginia, the company delivers immediate results to clients, addressing high-value, time-sensitive challenges not well served by other spectroscopy techniques. Its platform offers configurations for manufacturing process control, quality control, environmental monitoring, and formulation research.

ZwitterCo specializes in advanced membrane solutions for the treatment of highly impaired wastewater, enabling the reuse and recycling of water resources in industrial applications. The company's innovative reverse osmosis and nanofiltration technologies address the challenges of treating historically unfilterable streams by preventing fouling caused by organic molecules. ZwitterCo's membranes are chlorine-tolerant, back-washable, and resistant to irreversible fouling, which enhances their longevity and performance. By transforming wastewater from a liability into a valuable resource, ZwitterCo helps clients manage their water treatment needs more economically and sustainably, reducing chemical demands and improving operational efficiency.

Founded in 2015, Bond Pet Foods produces sustainable pet food using biotechnology. It creates animal protein through fermentation without slaughtering animals, meeting the nutritional requirements of companion pets.

Codetta Bio develops innovative multi-omic analysis tools for comprehensive biomarker measurement. Its platform combines digital PCR and qPCR technologies to understand genetic, environmental, lifestyle, and clinical factors contributing to individual health, enabling accurate insights from a single specimen.

Epitel is a digital health company developing a wearable, wireless EEG monitoring platform that enables accessible, reliable seizure detection. The system combines a cloud-based wearable sensor network with artificial intelligence to identify electrographic seizures, providing brain health insights for physicians, caregivers, and patients with neurological disorders to improve quality of life and care.

Meiogenix is a biotechnology company developing breeding technologies to uncover unexplored genetic diversity in organisms, expanding natural biodiversity and enabling the development of products to address global food, climate, sustainability, and industrial challenges. It uses chromosome-editing-based approaches to modulate the frequency of homologous recombination in eukaryotic cells, enabling natural breeding and delivering new products for farmers and industry.

SimBioSys is focused on advancing cancer care through its innovative Computational Microscope, which merges advanced simulation techniques with a wide array of experimental datasets. This technology enables researchers to gain insights into the cancer microenvironment, allowing them to observe tumor behavior, including cell phenotypes and interactions with surrounding tissues. By creating personalized virtual tumors from comprehensive diagnostic data, SimBioSys facilitates computational scenario analysis that enhances doctors' understanding of individual cases. This approach aims to improve decision-making and patient experiences in the realm of oncology, ultimately transforming cancer treatment.

InterVenn is a life science company focused on revolutionizing healthcare through the study of glycoproteomics, which involves glycosylated proteins that significantly influence protein function. By developing an innovative AI-powered platform, InterVenn decodes the complex glycoproteome, providing critical biological insights that were previously unattainable. This technology enables the identification, quantification, and classification of glycoproteomic signals in human blood and tissue, facilitating early detection and triaging of cancers, particularly ovarian cancer. InterVenn’s platform supports the creation of a diverse range of clinical applications, from disease screening to diagnostics, and has the potential to contribute to therapeutics. Founded by renowned experts, including Nobel Laureate Dr. Carolyn Bertozzi, InterVenn aims to advance personalized, predictive, and preventative healthcare solutions, enhancing patient outcomes and aiding pharmaceutical partners in their research and development efforts.

Stemson Therapeutics is a cell therapy company focused on restoring natural hair by generating new hair follicles. It uses induced pluripotent stem cells to create dermal papilla cells and combines them with a tissue engineering approach to produce a net new supply of hair follicles for patients experiencing hair loss. The company develops its proprietary methods to engineer cells capable of regenerating follicles, aiming to address emotional and social impact of hair loss. Founded in 2018, it is based in La Jolla, California.

BloodQ develops an analytical platform designed for cancer drug treatment. Its platform captures disease molecular signals in circulating DNA to improve sensitivity, specificity, and timing in diagnostic and disease management, thereby providing patients personalized cancer treatment.

Attune Neurosciences is a medical device company focused on enhancing human health and performance through the development of clinically proven, non-invasive neurostimulation products. The company aims to address sleep- and wake-related conditions by modulating brain activity, thereby assisting patients suffering from central nervous system disorders. In addition to supporting individual health, Attune Neurosciences also seeks to serve government and industrial applications, positioning its innovative solutions to benefit a broader range of stakeholders.

BRAINBox Solutions develops and manufactures diagnostic tests for traumatic brain injury, focusing on mild TBI. The company offers a multi-modality platform that combines blood biomarker panels with neurocognitive testing and point-of-care instruments to provide objective assessments of injury and recovery potential. Its quantitative test integrates injury-related blood biomarkers with computerized neurological assessments and delivers an AI-driven score to aid clinicians in predicting recovery and identifying ongoing symptoms. Founded in 2002 and based in Richmond, Virginia, BRAINBox Solutions serves healthcare providers with tools designed to improve diagnostic accuracy and prognosis for patients with mild TBI.

InterVenn is a life science company focused on revolutionizing healthcare through the study of glycoproteomics, which involves glycosylated proteins that significantly influence protein function. By developing an innovative AI-powered platform, InterVenn decodes the complex glycoproteome, providing critical biological insights that were previously unattainable. This technology enables the identification, quantification, and classification of glycoproteomic signals in human blood and tissue, facilitating early detection and triaging of cancers, particularly ovarian cancer. InterVenn’s platform supports the creation of a diverse range of clinical applications, from disease screening to diagnostics, and has the potential to contribute to therapeutics. Founded by renowned experts, including Nobel Laureate Dr. Carolyn Bertozzi, InterVenn aims to advance personalized, predictive, and preventative healthcare solutions, enhancing patient outcomes and aiding pharmaceutical partners in their research and development efforts.

IonPath Inc., established in 2014 and headquartered in Menlo Park, California, specializes in multiplexed ion beam imaging services for pathology. The company's core technology surpasses light microscopy, enabling it to analyze fresh, frozen, or FFPE tissues with high precision. This allows healthcare providers to diagnose cancer more accurately, ultimately improving human health through better insights into the tissue microenvironment at a single-cell level.

Tropic Biosciences UK Ltd, established in 2016 and based in Norwich, is a biotechnology company specializing in the development of commercial tropical crops. It employs advanced plant breeding and non-GMO gene editing techniques to create high-performing varieties, catering primarily to the coffee and banana industries. The company's mission is to promote grower wellbeing, consumer health, and sustainable environmental practices through its innovative, non-GMO methods, which significantly accelerate the breeding process to meet growing food demands and local community needs.

Intabio, Inc. is a biotechnology company founded in 2015 and based in Newark, California. It specializes in developing analytical solutions aimed at enhancing the efficiency of biopharmaceutical development and manufacturing. The company’s primary offering is the Blaze system, which includes a bench-top instrument, microfluidic chip, and reagent kit designed for the separation, quantitation, and molecular mass identity analysis of biotherapeutic proteins. Additionally, Intabio's microfluidic platform facilitates real-time characterization of intact protein isoforms, allowing for the identification of specific structural modifications. This technology enables biotherapeutic drug manufacturers to perform comprehensive analyses of antibody and protein biopharmaceuticals, resulting in significant improvements in throughput and cost-effectiveness compared to traditional methods.

InterVenn is a life science company focused on revolutionizing healthcare through the study of glycoproteomics, which involves glycosylated proteins that significantly influence protein function. By developing an innovative AI-powered platform, InterVenn decodes the complex glycoproteome, providing critical biological insights that were previously unattainable. This technology enables the identification, quantification, and classification of glycoproteomic signals in human blood and tissue, facilitating early detection and triaging of cancers, particularly ovarian cancer. InterVenn’s platform supports the creation of a diverse range of clinical applications, from disease screening to diagnostics, and has the potential to contribute to therapeutics. Founded by renowned experts, including Nobel Laureate Dr. Carolyn Bertozzi, InterVenn aims to advance personalized, predictive, and preventative healthcare solutions, enhancing patient outcomes and aiding pharmaceutical partners in their research and development efforts.

Intabio, Inc. is a biotechnology company founded in 2015 and based in Newark, California. It specializes in developing analytical solutions aimed at enhancing the efficiency of biopharmaceutical development and manufacturing. The company’s primary offering is the Blaze system, which includes a bench-top instrument, microfluidic chip, and reagent kit designed for the separation, quantitation, and molecular mass identity analysis of biotherapeutic proteins. Additionally, Intabio's microfluidic platform facilitates real-time characterization of intact protein isoforms, allowing for the identification of specific structural modifications. This technology enables biotherapeutic drug manufacturers to perform comprehensive analyses of antibody and protein biopharmaceuticals, resulting in significant improvements in throughput and cost-effectiveness compared to traditional methods.

IonPath Inc., established in 2014 and headquartered in Menlo Park, California, specializes in multiplexed ion beam imaging services for pathology. The company's core technology surpasses light microscopy, enabling it to analyze fresh, frozen, or FFPE tissues with high precision. This allows healthcare providers to diagnose cancer more accurately, ultimately improving human health through better insights into the tissue microenvironment at a single-cell level.

NanoCellect Biomedical, Inc., established in 2009 and headquartered in San Diego, California, specializes in developing innovative flow cytometry and cell sorting solutions for life science researchers. The company's flagship product, the WOLF Cell Sorter, employs a unique closed fluid-path microfluidic cartridge to facilitate efficient cell sorting while mitigating biohazard risks and shear stress issues common in traditional methods. Their portfolio of affordable, compact, and user-friendly instruments and consumables caters to various applications such as drug discovery, single-cell omics, cloning, antibody discovery, and basic research, empowering biomedical scientists with simplified cellular analysis and sorting capabilities.

Intabio, Inc. is a biotechnology company founded in 2015 and based in Newark, California. It specializes in developing analytical solutions aimed at enhancing the efficiency of biopharmaceutical development and manufacturing. The company’s primary offering is the Blaze system, which includes a bench-top instrument, microfluidic chip, and reagent kit designed for the separation, quantitation, and molecular mass identity analysis of biotherapeutic proteins. Additionally, Intabio's microfluidic platform facilitates real-time characterization of intact protein isoforms, allowing for the identification of specific structural modifications. This technology enables biotherapeutic drug manufacturers to perform comprehensive analyses of antibody and protein biopharmaceuticals, resulting in significant improvements in throughput and cost-effectiveness compared to traditional methods.

Akadeum Life Sciences develops bioseparation products that facilitate the removal of target cells from biological samples using microscopic micro-bubbles. Its products enable medical practitioners to efficiently perform downstream testing and analysis.

Adarza BioSystems is an early-stage medical diagnostics company based in St. Louis, Missouri, that specializes in developing a rapid and label-free biological assay platform for clinical and point-of-care samples. Founded in 2008, the company utilizes its innovative arrayed imaging reflectometry technology to enable the simultaneous detection of hundreds of analytes from a single drop of fluid. This platform allows healthcare professionals to conduct sophisticated tests in a matter of minutes, ensuring high sensitivity and specificity in the detection of multiplexed proteins. Adarza BioSystems aims to enhance diagnostic capabilities, improving patient outcomes through quicker and more accurate testing.

Synthomics, Inc. specializes in oligonucleotide synthesis solutions, providing advanced RNA and DNA synthesizers that enhance the efficiency and quality of oligonucleotide production. Based in Menlo Park, California, the company develops products for diverse applications, including research, diagnostics, pharmaceuticals, and agriculture. Their innovative synthesizer can accommodate up to 1,536 unique oligonucleotides simultaneously, significantly surpassing the industry standard of 96. This capability not only reduces reagent consumption but also lowers costs and improves turnaround times. Synthomics' flagship "Green Machine" further streamlines DNA synthesis, achieving cost reductions of 20 to 100 times while minimizing waste and enhancing overall quality. Their solutions support critical processes such as next generation sequencing, gene synthesis, gene editing, and PCR, making significant contributions to life sciences innovation.

Caribou Biosciences develops cellular engineering solutions based on CRISPR technologies, offering a gene editing platform with applications in human therapeutics, disease modeling, genomics research, and agricultural biotechnology.

Founded in 2010, Pivot Bio is a biotechnology company specializing in microbial nitrogen fertilizers. It harnesses naturally occurring microbes to provide nutrients to crops sustainably, aiming to reduce the need for petrochemical fertilizers and improve crop yield.

IonPath Inc., established in 2014 and headquartered in Menlo Park, California, specializes in multiplexed ion beam imaging services for pathology. The company's core technology surpasses light microscopy, enabling it to analyze fresh, frozen, or FFPE tissues with high precision. This allows healthcare providers to diagnose cancer more accurately, ultimately improving human health through better insights into the tissue microenvironment at a single-cell level.

Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. Founded in 2013 and headquartered in Emeryville, California, Zymergen employs a platform that integrates automation, machine learning, and genomics to enhance the efficiency of microbial strain optimization and production processes. This technology enables the company to improve existing manufacturing strains and facilitates the development of new products by engineering novel molecules from microbes. With additional offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, Zymergen aims to partner with nature to create innovative materials and products that deliver significant value across multiple sectors.

Caribou Biosciences develops cellular engineering solutions based on CRISPR technologies, offering a gene editing platform with applications in human therapeutics, disease modeling, genomics research, and agricultural biotechnology.

Zephyrus Biosciences, Inc. is a life science research tools company based in Berkeley, California, founded in 2013. The company specializes in developing and commercializing innovative tools for protein analysis at the single-cell level. Its flagship product, the scWestern System, allows for western blotting on individual cells, a significant advancement in the field of single-cell analysis. By utilizing microfluidics technology, the scWestern system partitions single cells into micro-wells, lyses them, and performs SDS-PAGE separation on each cell lysate. This technology facilitates the identification of cellular subpopulations, the analysis of enriched cell populations post-FACS sorting, and studies on cell signaling and cancer heterogeneity, among other applications. Researchers leverage Zephyrus's products to gain deeper insights into various biological fields, including cancer, stem cells, neurology, and human disease development, ultimately aiming to enhance healthcare outcomes.

Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. Founded in 2013 and headquartered in Emeryville, California, Zymergen employs a platform that integrates automation, machine learning, and genomics to enhance the efficiency of microbial strain optimization and production processes. This technology enables the company to improve existing manufacturing strains and facilitates the development of new products by engineering novel molecules from microbes. With additional offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, Zymergen aims to partner with nature to create innovative materials and products that deliver significant value across multiple sectors.